奥沙利铂联合替吉奥治疗晚期结直肠癌的疗效观察

Clinical Observation of Oxaliplatin Combined With Teggio in the Treatment of Advanced Colorectal Cancer

目的对晚期结直肠癌患者采用奥沙利铂联合替吉奥治疗的效果进行探究。方法搜集医院在2017年1月—2019年9月收治的晚期结直肠癌病例,从中找出符合样本纳入标准的96例纳入研究,按照治疗措施的差异展开1∶1分组,A组和B组两组患者各有48例。A组患者实施奥沙利铂联合氟尿嘧啶治疗,B组患者实施奥沙利铂联合替吉奥治疗。对比两组的疗效和不良反应。结果A组的总缓解率为47.9%,B组的总缓解率为70.8%,B组的总缓解率明显高于A组,差异有统计学意义(P<0.05);B组的恶心呕吐、肝功能减退、白细胞减少、贫血、血小板减少等不良反应发生率明显低于A组,差异有统计学意义(P<0.05);治疗前,两组的生活质量评分相比差异无统计学意义(P>0.05),治疗后,B组的生活质量评分明显高于A组,两组数据差异有统计学意义(P<0.05);A组的1年生存率为47.9%,B组的1年生存率为54.2%,B组的1年生存率与A组相比差异无统计学意义(P>0.05)。结论在晚期结直肠癌的治疗中,采用奥沙利铂联合替吉奥治疗具有很好的效果,能够较好地缓解患者的症状,可以提高患者的生活质量,而且还可以减少患者的不良反应,不过对于患者的远期疗效并没有显著改善。

Objective To explore the effect of oxaliplatin combined with ticgio treatment in patients with advanced colorectal cancer.Methods Collected the advanced colorectal cancer cases admitted in our hospital from January 2017 to September 2019,and found 96 cases that meet the sample inclusion criteria to be included in the study.According to the difference in treatment measures,they are divided into 1:1 groups,group A and group B.There were 48 cases in each of the two groups.Patients in group A were treated with oxaliplatin combined with fluorouracil,and patients in group B were treated with oxaliplatin combined with tigio.The efficacy and adverse reactions of the two groups were compared.Results The total remission rate of group A was 47.9%,the total remission rate of group B was 70.8%,the total remission rate of group B was significantly higher than that of group A,the difference was statistically significant(P<0.05).The incidence of adverse reactions such as nausea and vomiting,liver dysfunction,leukopenia,anemia,thrombocytopenia in group B was significantly lower than that of group A,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the quality of life score between the two groups(P>0.05).After treatment,the quality of life score in group B was significantly higher than that in group A,and the difference between the two groups was statistically significant(P<0.05).The 1-year survival rate of group A was 47.9%,and the 1-year survival rate of group B was 54.2%.There was no significant difference in the 1-year survival rate of group B and group A(P>0.05).Conclusion In the treatment of advanced colorectal cancer,the treatment of oxaliplatin combined with tigeo has a good effect,which can relieve the symptoms of the patients,improve the quality of life of the patients,and reduce the adverse reactions of the patients.But the long-term efficacy for patients has not been significantly improved.